TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy …
ST Tagawa, AV Balar, DP Petrylak… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-
based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited …
based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited …
Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis
Z Hepp, SN Shah, K Smoyer, P Vadagam - Journal of Managed Care & …, 2021 - jmcp.org
BACKGROUND: Several immuno-oncology (IO) agents targeting programmed death-1 or
programmed death-ligand 1 (PD-1/L1) are approved second-line therapy options for …
programmed death-ligand 1 (PD-1/L1) are approved second-line therapy options for …
Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors
Background Immune checkpoint inhibitors (ICIs) represent an appealing treatment for
patients with advanced urothelial cancer (aUC) and a poor performance status (PS) …
patients with advanced urothelial cancer (aUC) and a poor performance status (PS) …
[HTML][HTML] Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study
J Ruiz-Bañobre, A Molina-Díaz, O Fernández-Calvo… - ESMO open, 2021 - Elsevier
Background Few studies have investigated the safety and efficacy of anti-PD-(L) 1
antibodies in metastatic urothelial carcinoma (mUC) in daily clinical practice. Knowledge …
antibodies in metastatic urothelial carcinoma (mUC) in daily clinical practice. Knowledge …
[HTML][HTML] Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States
DM Geynisman, E Broughton, Y Hao, Y Zhang… - … Oncology: Seminars and …, 2022 - Elsevier
Introduction This large-scale, US-based study characterized real-world treatment patterns
and clinical outcomes in patients with advanced or metastatic urothelial carcinoma (aUC) …
and clinical outcomes in patients with advanced or metastatic urothelial carcinoma (aUC) …
Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: analysis of a Japanese nationwide cohort
K Ito, T Kobayashi, T Kojima, K Hikami… - Cancer …, 2021 - Wiley Online Library
Background The benefits of pembrolizumab in patients with advanced urothelial carcinoma
(UC) and impaired performance status (PS) remain unknown. This study assessed the safety …
(UC) and impaired performance status (PS) remain unknown. This study assessed the safety …
Clinical outcomes of patients with metastatic urothelial carcinoma after progression to immune checkpoint inhibitors: a retrospective analysis by the Meet-Uro Group …
Background: Immune checkpoint inhibitors (ICIs) are currently the standard of care for
metastatic urothelial cancer (mUC) after the failure of previous platinum-based …
metastatic urothelial cancer (mUC) after the failure of previous platinum-based …
Clinical and patient-reported outcomes of advanced urothelial carcinoma following discontinuation of PD-1/L1 inhibitor therapy
AK Morgans, S Grewal, Z Hepp, R Fuldeore… - Clinical Genitourinary …, 2022 - Elsevier
Introduction The patterns of care and attrition of locally advanced or metastatic urothelial
carcinoma (la/mUC) patients eligible for systemic therapy following PD-1/L1 inhibitors are …
carcinoma (la/mUC) patients eligible for systemic therapy following PD-1/L1 inhibitors are …
[HTML][HTML] Real-world burden of illness and unmet need in locally advanced or metastatic urothelial carcinoma following discontinuation of PD-1/L1 inhibitor therapy: A …
AK Morgans, Z Hepp, SN Shah, A Shah… - … Oncology: Seminars and …, 2021 - Elsevier
Background Several programmed death-1 or death-ligand 1 (PD-1/L1) inhibitors are
approved first-or second-line therapies for locally advanced or metastatic urothelial …
approved first-or second-line therapies for locally advanced or metastatic urothelial …
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: results of real-life experiences
D Tural, ÖF Ölmez, AT Sümbül, M Artaç, N Özhan… - European urology …, 2021 - Elsevier
Background Atezolizumab (ATZ) has demonstrated antitumor activity and manageable
safety in previous studies in patients with locally advanced or metastatic platinum-resistant …
safety in previous studies in patients with locally advanced or metastatic platinum-resistant …